A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study
Phase of Trial: Phase II/III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Anagrelide; Interferon alpha; Peginterferon alfa
- Indications Essential thrombocythaemia
- Focus Therapeutic Use
- Acronyms RUXBETA
- 08 Dec 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.
- 16 Jan 2017 Status changed from not yet recruiting to recruiting.
- 17 Nov 2016 New trial record